KYMR Kymera Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KYMR

Price (delayed)

$20.76

Market cap

$1.15B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.86

Enterprise value

$1.15B

Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on advancing the field of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ targeted protein ...

Highlights
Kymera Therapeutics's quick ratio has decreased by 16% QoQ but it has increased by 7% YoY
The company's EPS fell by 4% QoQ but it rose by 3.1% YoY
The equity has contracted by 23% YoY and by 9% from the previous quarter
KYMR's net income is down by 9% year-on-year and by 6% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kymeratx.com
Peers: OMGA

Key stats

What are the main financial stats of KYMR
Market
Shares outstanding
55.49M
Market cap
$1.15B
Enterprise value
$1.15B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$167.26M
EBITDA
-$163.76M
Free cash flow
-$173.64M
Per share
EPS
-$2.86
Free cash flow per share
-$2.97
Book value per share
$7.14
Revenue per share
$0
TBVPS
$9.45
Balance sheet
Total assets
$552.38M
Total liabilities
$156.84M
Debt
$80.84M
Equity
$395.54M
Working capital
$312.53M
Liquidity
Debt to equity
0.2
Current ratio
5.95
Quick ratio
5.76
Net debt/EBITDA
0.04
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-28.5%
Return on equity
-37.6%
Return on invested capital
-32.4%
Return on capital employed
-34.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KYMR stock price

How has the Kymera Therapeutics stock price performed over time
Intraday
5.33%
1 week
5.17%
1 month
85.03%
1 year
-28.36%
YTD
-16.83%
QTD
49.35%

Financial performance

How have Kymera Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$231.69M
Net income
-$167.46M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 14% YoY and by 3.5% QoQ
KYMR's net income is down by 9% year-on-year and by 6% since the previous quarter

Growth

What is Kymera Therapeutics's growth rate over time

Valuation

What is Kymera Therapeutics stock price valuation
P/E
N/A
P/B
2.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 4% QoQ but it rose by 3.1% YoY
The equity has contracted by 23% YoY and by 9% from the previous quarter
The stock's price to book (P/B) is 3.9% more than its last 4 quarters average of 2.8

Efficiency

How efficient is Kymera Therapeutics business performance
The company's return on equity fell by 13% QoQ and by 10% YoY
KYMR's return on assets is down by 10% since the previous quarter and by 8% year-on-year
The return on invested capital has grown by 10% year-on-year but it has declined by 2.2% since the previous quarter

Dividends

What is KYMR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KYMR.

Financial health

How did Kymera Therapeutics financials performed over time
The total liabilities has grown by 25% YoY and by 7% from the previous quarter
The current ratio has declined by 16% since the previous quarter but it has increased by 10% year-on-year
KYMR's debt is 80% smaller than its equity
The equity has contracted by 23% YoY and by 9% from the previous quarter
Kymera Therapeutics's debt to equity has increased by 18% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.